Anika Therapeutics (ANIK) Payables (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Payables data on file, last reported at $6.3 million in Q1 2026.

• On a quarterly basis, Payables rose 20.13% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $6.3 million, a 20.13% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 7.55% from the prior year.
• Payables for Q1 2026 stood at $6.3 million, up from $6.0 million in the prior quarter.
• Over the last five years, Payables for ANIK reached as high as $10.0 million in Q1 2024 and fell as low as $4.7 million in Q3 2025.
• Historically, Payables has averaged $7.3 million across 5 years, with a median of $7.4 million in 2022.
• Across the five-year window, Payables gained 25.81% in 2024 and sank 52.26% in 2025, its largest moves.
• Year by year, Payables stood at $9.1 million in 2022, then sank by 31.74% to $6.2 million in 2023, then retreated by 9.32% to $5.6 million in 2024, then rose by 7.55% to $6.0 million in 2025, then increased by 4.93% to $6.3 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $6.3 million in Q1 2026, $6.0 million in Q4 2025, and $4.7 million in Q3 2025.